FTSE 100’s second-biggest firm will also retain HQ in Cambridge and maintain its London listing
The drugmaker AstraZeneca is preparing to directly list its shares on the New York Stock Exchange, but said it will continue to be listed in London amid speculation over its future.
The FTSE 100 company said its direct listing in New York will replace trading in its “American depositary receipts” (ADRs) – which give US investors exposure to a non-US company – on the Nasdaq.
Background
This developing story continues to unfold as more information becomes available. The situation has drawn attention from various stakeholders and continues to be monitored closely.
Analysis
Industry experts suggest that this development could have significant implications moving forward. The broader context of this news reflects ongoing trends in the sector.
What This Means
The implications of this news extend beyond the immediate circumstances. Stakeholders are closely watching how this situation develops and what it might mean for future developments in this area.